[go: up one dir, main page]

WO2024180520A1 - Nouveaux inhibiteurs d'atx - Google Patents

Nouveaux inhibiteurs d'atx Download PDF

Info

Publication number
WO2024180520A1
WO2024180520A1 PCT/IB2024/052000 IB2024052000W WO2024180520A1 WO 2024180520 A1 WO2024180520 A1 WO 2024180520A1 IB 2024052000 W IB2024052000 W IB 2024052000W WO 2024180520 A1 WO2024180520 A1 WO 2024180520A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxo
chloro
indene
pyrazol
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IB2024/052000
Other languages
English (en)
Inventor
Kumaragurubaran NAGASWAMY
Rajesh Bahekar
Vijay PRAJAPATI
Darshan Joshi
Harsh Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Zydus Lifesciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zydus Lifesciences Ltd filed Critical Zydus Lifesciences Ltd
Publication of WO2024180520A1 publication Critical patent/WO2024180520A1/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Definitions

  • the present invention describe novel compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs as ATX inhibitors for the treatment and prophylaxis of conditions or a disorder caused by autotaxin (ATX) activation or increased concentration of lysophosphatidic acid (LPA) and also a pharmaceutical composition containing the same.
  • ATX autotaxin
  • LPA lysophosphatidic acid
  • ATX enzyme is important for converting Lysophosphatidylcholine (LPC) into LPA, as a bioactive signaling molecule.
  • LPC Lysophosphatidylcholine
  • ATX is a secreted enzyme of the ectonucleotide phosphatase family, also known as Ectonucleotide Pyrophosphatase/ Phosphodiesterase 2 (ENPP-2 or NPP2).
  • ENPP-2 or NPP2 Ectonucleotide Pyrophosphatase/ Phosphodiesterase 2
  • LPA is a bioactive lipid that affects migration, proliferation and survival of various cell types. LPA mediates variety of cellular and biological actions through LPA receptors (LPAR).
  • the LPA shows broad tissue expression and it can couple to at least six distinct G proteins, known as LPAR1-6, which in turn, feed into multiple effector systems (Yung, Y.C. et al., J. Lipid Res. 2014, 55, 1192 and Kihara, Y. et al., Exp. Cell Res. 2015, 333, 171). Since the LPA level in plasma is highly related to the activity of ATX, it is believed that ATX is an important supply source of extracellular LPA.
  • LPA lymphocyte homing chronic inflammation
  • neuropathic pain fibrotic diseases
  • fibrotic diseases such as Idiopathic Pulmonary Fibrosis (IPF), thrombosis and cholestatic pruritus which caused and / or propagated by increased LPA levels and / or activation of ATX.
  • IPF Idiopathic Pulmonary Fibrosis
  • thrombosis thrombosis
  • IPF is characterized as a progressive scarring of lung tissue which leads to worsening lung function and is ultimately fatal within 3-5 years from the onset of symptoms.
  • LPAR1 has been identified to be the predominant LPA receptor (Tager, A. M. et al., Nat. Med. 2008, 14, 45 and Montesi, S. B. et al., BMC Pulm. Med. 2014). In the lung fibroblasts of an IPF patient, LPAR1 was found to be responsible for enhanced fibroblast cell migration and vascular leak.
  • LPAR1 antagonists will be a potential drug target for the treatment of IPF.
  • several LPAR1 antagonists have been reported, and some of these compounds are currently being evaluated for the treatment of IPF (Budd, D. C et al.., Future Med. Chem. 2013, 5, 1935; Qian, Y. et al., J. Med. Chem. 2012, 55, 7920 and Terakado, M. et al., ACS Med. Chem. Lett. 2016, 7, 913).
  • Fibrosis can develop in the liver, kidney, lung, dermis, vasculature, gut and other sites. Fibrosis develops due to action of pathways including growth factors, cytokines, integrin and lipids.
  • ATX, LPA and LPAR pathways have been implicated in fibrotic disease. Increased levels of ATX, LPA and LPARs observed in various rodent models of fibrosis and in patient fluids and biopsy tissues. LPA can induce proliferative, survival and chemotactic responses in cells known to be critical in fibrotic disease, including: fibroblasts, smooth muscle cells, macrophages, epithelial and endothelial cells and leukocytes.
  • Inhibitors of LPARs indicate that antagonism of receptors within this pathway blocked or reversed fibrosis in the lung, liver, kidney and skin in rodents. Accordingly in fibrotic diseases, it is desirable to lower LPA levels. This can be accomplished through inhibition of enzymes involved in LPA biosynthesis, such as ATX.
  • WO2022258693 W02022149010, W02022100727, WO2022074459, W02022003557, W02022003377, WO2021088957, WO2021078227, WO2021143753, WO2019228403, WO2019108943, WO 2019029620, WO2019223721, W02019158107, WO201815312, WO2017152062, W02017050791, W02017050792, W02017050747, W02017050732, WO2016144706, WO2016144704, WO2016028686, WO2015144605, W02015042053, W02015042052, WO2015154023, WO2015175171, W02015077503, W02015077502, W0201504830L WO2014139882.
  • ATX inhibitors for use in the treatment and / or prophylaxis of physiological and / or pathophysiological conditions such as cancer, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis which are caused, medicated and / or propagated by increased LPA levels and / or the activation of ATX.
  • the present invention describe novel compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs as ATX inhibitors for treatment and prophylaxis of conditions or a disorder caused by ATX activation or increased concentration of LPA and also a pharmaceutical composition containing the same.
  • Embodiments of the present invention include the compounds herein, pharmaceutically acceptable salts thereof, any physical forms thereof including solvates and hydrates, preparation of the compounds, intermediates and pharmaceutical compositions and formulations thereof.
  • An embodiment of the present invention provides novel compounds represented by the general formula (I), their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs and pharmaceutical compositions containing them or their mixtures thereof.
  • the use of novel compounds their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs of the present invention is use for the treatment of cancer, chronic inflammation, neuropathic pain, fibrotic diseases, by administering a therapeutically effective and non-toxic amount of novel compounds of general formula (I) or their pharmaceutically acceptable compositions to the mammals.
  • the present invention includes a method for the treatment of at least one of cancer, chronic inflammation, neuropathic pain, fibrotic diseases mediated in part by ATX comprising administering to a subject in need thereof a therapeutically effective amount of a compound or salt of the novel compound of formula (I).
  • the compound of formula (I) can be administered in combination with other therapeutic agents.
  • the present invention relates to the novel compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs represents below;
  • R 1 and R 2 are independently selected from -H, halo, -(Ci-Ce)alkyl, (Ci-Ce)alkoxy, - (CH 2 ) q CF 3 , -CN, -O(CH 2 ) q CF 3 , -(CH 2 ) q OR a , -COOR a , -C(O)NR a R b , (C 3 -C 7 )cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocyclyl; E is selected from -CH 2 or -O-; when E is -O- then n is 1; when E is -CH 2 then n is 1 or 2;
  • Ring A is selected from aryl or heteroaryl
  • Ring B is selected from substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or heterocyclyl;
  • R 3 is selected from -H, halo, -(CH 2 ) r CF 3 , -CN, -O(CH 2 ) r CF 3 , -(CH 2 ) r OR d , - (CR d R e ) r NR d R e , or -NR d R e , -(C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl , ( -C ⁇ alkoxy, (C C 6 )acyloxy, heterocyclyl wherein alkyl, cycloalkyl, alkoxy, acyloxy, heterocyclyl are substituted or unsubstituted;
  • R 4 and R 5 are independently selected from -H, halo, -(Ci-C 6 )alkyl, (Ci-C 6 )alkoxy, - (CH 2 ) S CF 3 , -CN, -O(CH 2 ) S CF 3 , -(CH 2 ) S OR S , or (C 3 -C 7 )cycloalkyl;
  • X, Y and Z are independently selected from -C or -N; m is selected from 1 or 2; p is selected from 0 or 1; q, r and s are independently selected from 0, 1, 2 or 3;
  • R a , R b , R c , R d , R e , R f , R s , R h and R 1 are independently selected from H, -OH, (Ci-C 6 )alkyl, haloalkyl, or (C 3 -C 7 )cycloalkyl
  • novel compounds of the general formula (I-a) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs represents below;
  • R 1 and R 2 are independently selected from -H, halo, -(Ci-Ce)alkyl, (Ci-Ce)alkoxy, - (CH 2 ) q CF 3 , -CN, -O(CH 2 ) q CF 3 , -(CH 2 ) q OR a , -COOR a , -C(O)NR a R b , (C 3 -C 7 )cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocyclyl;
  • E is selected from -CH 2 or -O-; when E is -O- then n is 1; when E is -CH 2 then n is 1 or 2;
  • Ring A is selected from aryl or heteroaryl
  • Ring B is selected from substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or heterocyclyl;
  • R 3 is selected from -H, halo, substituted or unsubstituted -(Ci-Ce)alkyl, (C 3 -C 7 )cycloalkyl , (Ci-C 6 )alkoxy, (Ci-C 6 )acyloxy, -(CH 2 ) r CF 3 , -CN, -O(CH 2 ) r CF 3 , -(CH 2 ) r OR d , - (CR d R e ) r NR d R e , or -NR d R e ;
  • R 4 and R 5 are independently selected from -H, halo, -(Ci-Ce)alkyl, (Ci-Ce)alkoxy, - (CH 2 ) S CF 3 , -CN, -O(CH 2 ) S CF 3 , -(CH 2 ) S OR S , or (C 3 -C 7 )cycloalkyl;
  • X, Y and Z are independently selected from -C or -N; m is selected from 1 or 2; p is selected from 0 or 1; q, r and s are independently selected from 0, 1, 2 or 3;
  • R a , R b , R c , R d , R e , R f , R s , R h and R 1 are independently selected from -H, -OH, (Ci-Ce)alkyl, haloalkyl, or (C 3 -C 7 )cycloalkyl
  • R 1 and R 2 are independently selected from -H, halo, -COOR a , substituted or unsubstituted heteroaryl;
  • Ring A is selected from aryl
  • Ring B is selected from substituted or unsubstituted heteroaryl
  • R 3 is selected from -(CH 2 ) r OR d , -(Ci-Ce)alkyl;
  • R 4 and R 5 are independently selected from halo; p is selected form 0; q is selected from 2;
  • R a and R d are independently selected from -H.
  • novel compounds of the general formula (I-b) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and Dolvmorohs reoresents below;
  • R 1 and R 2 are independently selected from -H, halo, -(Ci-Ce)alkyl, (Ci-Ce)alkoxy, - (CH 2 ) q CF 3 , -CN, -O(CH 2 ) q CF 3 , -(CH 2 ) q OR a , -COOR a , -C(O)NR a R b , (C 3 -C 7 )cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocyclyl;
  • E is selected from -CH 2 or -O-; when E is -O- then n is 1; when E is -CH 2 then n is 1 or 2;
  • Ring A is selected from aryl or heteroaryl
  • Ring B is selected from substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or heterocyclyl;
  • R 3 is selected from -H, halo, substituted or unsubstituted -(Ci-C 6 )alkyl, (C 3 -C 7 )cycloalkyl , (Ci-C 6 )alkoxy, (Ci-C 6 )acyloxy, -(CH 2 ) r CF 3 , -CN, -O(CH 2 ) r CF 3 , -(CH 2 ) r OR d , - (CR d R e ) r NR d R e , or -NR d R e ;
  • R 4 and R 5 are independently selected from -H, halo, -(Ci-C 6 )alkyl, (Ci-C 6 )alkoxy, - (CH 2 ) S CF 3 , -CN, -O(CH 2 ) S CF 3 , -(CH 2 ) S OR S , or (C 3 -C 7 )cycloalkyl;
  • X, Y and Z are independently selected from -C or -N; m is selected from 1 or 2; p is selected from 0 or 1; q, r and s are independently selected from 0, 1, 2 or 3;
  • R a , R b , R c , R d , R e , R f , R s , R h and R 1 are independently selected from H, -OH, (Ci-Ce)alkyl, haloalkyl, or (C 3 -C 7 )cycloalkyl
  • R 1 and R 2 may be selected from -H, halo, -(Ci-Ce)alkyl, -COOR a , -C(O)NR a R b , substituted or unsubstituted aryl, (C 3 -C7)cycloalkyl, substituted or unsubstituted heteroaryl;
  • Preferred Ring A may be selected from aryl or heteroaryl
  • Preferred Ring B may be selected from substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
  • Preferred R 3 may be selected from -H, -(Ci-Ce)alkyl, -(CH 2 ) r CF 3 , -(CH 2 ) r OR d , (C 3 - C7)cycloalkyl, or heterocyclyl;
  • R 4 and R 5 may be selected from -H, halo, -(Ci-C 6 )alkyl, (Ci-C 6 )alkoxy, - (CH 2 ) S CF 3 , -CN, -O(CH 2 ) S CF 3 ;
  • Preferred X, Y and Z may be selected from -C or -N;
  • R a , R b , R c , R d , R e , R f , R s , R h and R 1 may be selected from -H, (Ci-Ce)alkyl, -OH;
  • the groups, radicals described above may be selected from:
  • Alkyl as well as other groups having the prefix “alk”, such as alkoxy and alkanoyl, means carbon chain which may either be linear or branched, and combinations thereof, unless the carbon chain is defined otherwise.
  • alkyl group include but not limited to methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert.-butyl, pentyl, hexyl etc. Where the specified number of carbon atoms permits e.g. from C 3 .io, the term alkyl also includes cycloalkyl groups, and combinations of linear or branched alkyl chains combined with cycloalkyl structures.
  • Cycloalkyl is the subset of alkyl and means saturated carbocyclic ring having a specified number of carbon atoms, preferably 3-6 carbon atoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl etc. A cycloalkyl group generally is monocyclic unless otherwise stated. Cycloalkyl groups are saturated unless and otherwise stated.
  • Haloalkyl group is selected from an alkyl radical, as defined above, suitably substituted with one or more halogens; such as fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, mono or polyhalo substituted methyl, ethyl, propyl, butyl, pentyl or hexyl groups;
  • Aryl means a mono- or polycyclic aromatic ring system containing carbon ring atoms.
  • the preferred aryls are monocyclic or bicyclic 6-10 membered aromatic ring systems. Phenyl and naphthyl are preferred aryls.
  • Heterocyclyl or “heterocyclic” group used either alone or in combination with other radicals, is selected from suitable saturated, partially saturated or unsaturated aromatic or non-aromatic mono, bi or tricyclic radicals, containing one or more heteroatoms selected from nitrogen, sulfur and oxygen, more preferably selected from aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, 4- methylpiprrazinyl, 4-hydroxypiperidinyl, 2-oxopiperidinyl, 4-oxopiperidinyl, 2- oxopiperazinyl, 3-oxopiperazinyl, morpholinyl, thiomorpholinyl, dioxothiomorpholinyl, 2- oxomorpholinyl, azepinyl, diazepinyl, oxapinyl, thiazepinyl, oxazolidinyl, o
  • Heteroaryl or “heteroaromatic” group used either alone or in combination with other radicals is selected from suitable single or fused mono, bi or tricyclic aromatic heterocyclic radicals containing one or more hetero atoms selected from O, N or S, more preferably the groups are selected from pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, isothiazolyl, imidazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, benzofuranyl, benzothienyl, indolinyl, indolyl, azaindolyl, azaindolinyl, pyrazolopyrimidinyl, azaquinazolinyl, pyridofuranyl, pyridothienyl, thienopyrimidyl, quinolinyl,
  • Alkoxy group used either alone or in combination with other radicals, denotes a linear or branched radical containing one to six carbon attached to oxygen atom, selected from Methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, sec-butoxy, isobutoxy, pentyloxy, hexyloxy and the like;
  • “Acyloxy” group used either alone or in combination with other radicals is selected from groups containing one to eight carbons, more preferably selected from formyl, acetyl, propanoyl, butanoyl, pentanoyl , benzoyl and the like; "Halo” or “halogen” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom;
  • Suitable groups and substituents on the groups may be selected from those described anywhere in the specification.
  • substituted means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. Substitution selected from hydrogen, deuterium, hydroxy, cyano, halo, nitro, haloalkyl, oxo, (Ci-C 6 )alkyl, (C 3 -C 6 )cycloalkyl, aminoalkyl, alkoxyalkyl, alkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, aralkyl, heterocyclylalkyl, alkylsulfonyloxy.
  • “Pharmaceutically acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of the basic residues.
  • Such conventional non-toxic salts include, but are not limited to, those derived from inorganic and organic acids selected from 1, 2-ethanedisulfonic, 2- acetoxybenzoic, 2-hydroxyethanesulfonic, acetic, ascorbic, benzenesulfonic, benzoic, bicarbonic, carbonic, citric, eidetic, ethane disulfonic, ethane sulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, glycollyarsanilic, hexylresorcinic, hydrabamic, hydrobromic, hydrochloric, hydroiodide, hydroxymaleic, hydroxynaphthoic, is
  • ‘optional’ or ‘optionally’ means that the subsequent described event or circumstance may or may not occur, and the description includes instances where the event or circumstance occur and instances in which it does not.
  • ‘optionally substituted alkyl’ means either ‘alkyl’ or ‘substituted alkyl’. Further an optionally substituted group means unsubstituted.
  • structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms.
  • Particularly useful compounds may be selected from but not limited to the following; Table: 1
  • DIEA Diisopropyl ethyl amine
  • DMEDA 1,2-Dimethyl ethylene diamine
  • NaHCCh Sodium bicarbonate/sodium hydrogen carbonate
  • novel compounds of the present invention were prepared using the reactions and techniques described below, together with conventional techniques known to those skilled in the art of organic synthesis, or variations thereon as appreciated by those skilled in the art.
  • the reactions can be performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected.
  • Preferred methods include, but not limited to those described below, where all symbols are as defined earlier unless and otherwise defined below.
  • the compounds (IV) can be obtained by reacting compounds of the formula (II) with (III) inpresence of base such as Na 2 CO 3 , K 2 CO 3 Cs 2 CO 3 etc. in solvent such as THF, DMF etc.
  • base such as Na 2 CO 3 , K 2 CO 3 Cs 2 CO 3 etc.
  • solvent such as THF, DMF etc.
  • Step-1 Preparation of ethyl 6'-chloro-2'-oxo-F3-dihvdrospirolindene-2,3'-indoline1-5- carboxylate (3)
  • Step-2 ethyl 6'-chloro-2'-oxo-T-phenyl-l,3-dihvdrospirorindene-2,3'-indoline1-5- carboxylate (4)
  • Step-3 6'-chloro-2'-oxo-T-phenyl-L3-dihydrospirorindene-2,3'-indoline1-5-carboxylic acid
  • Compound 1 ethyl 6'-chloro-2'-oxo-T-phenyl-l,3-dihydrospiro[indene-2,3'-indoline]-5- carboxylate (0.21 g, 0.50 mmol) was dissolved in ethanol (2.1 mL) at room temperature. Aqueous NaOH solution (1.22 mL, 1.50 mmol) was dropwise added to the reaction mixture at room temperature and stirred for 5h.
  • Autotaxin activity was measured by determining the amount of Choline released from LPC 16:0 using Amplite® Choline Quantitation Kit (AAT Bioquest, 40007).
  • 5 pl of 20 nM purified recombinant human autotaxin (Echelon, E-4000) was mixed with lOpl of test compound (concentration range) in black 96 well plate in assay buffer (50 mM Tris-HCl pH 8.0, 500 mM NaCl, 5 mM KC1, 5 mM CaCl 2 , 0.1% Fatty acid free BSA) and incubated for 10 minutes at room temperature.
  • ATX inhibitory activity for representative compounds are listed in the Table 2.
  • the novel compounds of the present invention can be formulated into suitable pharmaceutically acceptable compositions by combining with suitable excipients by techniques and processes and concentrations as are well known.
  • the pharmaceutical compositions further comprise an effective amount of an ATX inhibitor.
  • the dosage of ATX inhibitors may vary within wide limits and should be adjusted, in each particular case, to the individual conditions.
  • the compounds of formula (I), or pharmaceutical compositions containing them are useful as a medicament for the inhibition of ATX activity and suitable for humans and other warm blooded animals, and may be administered either by oral, topical or parenteral administration.
  • the quantity of active component, that is, the novel compounds of formula (I) according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon several factors such as the particular application method, the potency of the particular compound and the desired concentration.
  • composition comprising compound of general formula (I), their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs having pharmaceutically acceptable carriers, solvents, diluents, excipients and other media normally employed in their manufacture.
  • the present invention includes a method for the treatment of at least one of cancer, chronic inflammation, neuropathic pain, fibrotic diseases mediated in part by ATX comprising administering to a subject in need thereof a therapeutically effective amount of a compound or salt of the novel compound of formula (I).
  • the compound of formula (I) may be used alone or in any combination with one or more therapeutic agents such as anti-inflammatory agents, antitumor agents, ant fibrotic agents, autotaxin inhibitors, immunomodulators and cardiovascular agents and other therapeutic agents which are known to skilled medical practitioner.
  • therapeutic agents such as anti-inflammatory agents, antitumor agents, ant fibrotic agents, autotaxin inhibitors, immunomodulators and cardiovascular agents and other therapeutic agents which are known to skilled medical practitioner.
  • the selection of such therapeutic agents may be depend upon the type of disease and its severity, condition of patient being treated, and other medications being taken by the patients, etc.
  • compound of formula (I) of the present invention may be used in combination with one or more suitable pharmaceutically active agents selected from following therapeutic agents in any combination with tyrosine kinase inhibitors and pyridones class of therapeutic agents.
  • suitable pharmaceutically active agents selected from following therapeutic agents in any combination with tyrosine kinase inhibitors and pyridones class of therapeutic agents.
  • Nintedanib is tyrosine kinase inhibitors class of drug
  • Pirfenidone is pyridones class of drug.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule générale (I), leurs sels pharmaceutiquement acceptables, leurs solvates, énantiomères, diastéréomères et polymorphes pharmaceutiquement acceptables. L'invention concerne également des procédés de préparation des composés de l'invention, des compositions pharmaceutiques contenant les composés et leur utilisation en tant qu'inhibiteurs d'ATX. (I)
PCT/IB2024/052000 2023-03-02 2024-03-01 Nouveaux inhibiteurs d'atx Pending WO2024180520A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202321014153 2023-03-02
IN202321014153 2023-03-02

Publications (1)

Publication Number Publication Date
WO2024180520A1 true WO2024180520A1 (fr) 2024-09-06

Family

ID=92589272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/052000 Pending WO2024180520A1 (fr) 2023-03-02 2024-03-01 Nouveaux inhibiteurs d'atx

Country Status (2)

Country Link
TW (1) TW202502735A (fr)
WO (1) WO2024180520A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012786A1 (fr) * 1986-07-10 1993-07-08 Howard Harry R Jr Derives d'indolinone
WO2016191427A1 (fr) * 2015-05-27 2016-12-01 Pharmakea, Inc. Inhibiteurs d'autotaxine et leurs utilisations
WO2022149010A1 (fr) * 2021-01-05 2022-07-14 Cadila Healthcare Limited Nouveaux inhibiteurs de l'autotaxine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012786A1 (fr) * 1986-07-10 1993-07-08 Howard Harry R Jr Derives d'indolinone
WO2016191427A1 (fr) * 2015-05-27 2016-12-01 Pharmakea, Inc. Inhibiteurs d'autotaxine et leurs utilisations
WO2022149010A1 (fr) * 2021-01-05 2022-07-14 Cadila Healthcare Limited Nouveaux inhibiteurs de l'autotaxine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NIKOLAOU AIKATERINI, KOKOTOU MAROULA G., LIMNIOS DIMITRIS, PSARRA ANASTASIA, KOKOTOS GEORGE: "Autotaxin inhibitors: a patent review (2012-2016)", EXPERT OPINION ON THERAPEUTIC PATENTS, TAYLOR & FRANCIS, GB, vol. 27, no. 7, 3 July 2017 (2017-07-03), GB , pages 815 - 829, XP055793570, ISSN: 1354-3776, DOI: 10.1080/13543776.2017.1323331 *
TAN ZEHUI, LEI HONGRUI, GUO MING, CHEN YUXIANG, ZHAI XIN: "An updated patent review of autotaxin inhibitors (2017–present)", EXPERT OPINION ON THERAPEUTIC PATENTS, TAYLOR & FRANCIS, GB, 19 December 2020 (2020-12-19), GB , pages 1 - 14, XP055793571, ISSN: 1354-3776, DOI: 10.1080/13543776.2021.1867106 *

Also Published As

Publication number Publication date
TW202502735A (zh) 2025-01-16

Similar Documents

Publication Publication Date Title
AU2019237992B2 (en) Oxadiazole transient receptor potential channel inhibitors
WO2022135572A1 (fr) Dérivé à cinq chaînons et dérivé cyclique à cinq chaînons et leur utilisation médicale
US10011609B2 (en) Heterocyclic compounds
AU2016272258A1 (en) Pyrido(3,4-d)pyrimidine derivative and pharmaceutically acceptable salt thereof
CA3108809C (fr) Composes heteroaromatiques, compositions pharmaceutiques et utilisationsconnexes
US20240216357A1 (en) Polycyclic compound and application thereof
JPWO2017006953A1 (ja) ＴｒｋＡ阻害活性を有する複素環誘導体
EP3544979A1 (fr) Oxadiazolones en tant qu'inhibiteurs de canal potentiel récepteur transitoire
KR20200013718A (ko) 바닌 억제제로서의 헤테로방향족 화합물
JPWO2017135399A1 (ja) ＴｒｋＡ阻害活性を有する含窒素複素環および炭素環誘導体
TW200936141A (en) Substituted heteroarylamide oxazepinopyrimidone derivatives
JP2022523477A (ja) ピロロピリミジン誘導体及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防又は治療用薬学的組成物
ES2363672T3 (es) TRIAZOLO[1,5-a]QUINOLINAS COMO LIGANDOS DEL RECEPTOR A3 DE ADENOSINA.
WO2013153539A1 (fr) Composés tricycliques à titre d'inhibiteurs de kinases tec
JP2021513530A (ja) テトラヒドロイソキノリン化合物、その調製方法、そのような化合物を含む医薬組成物およびその使用
WO2015199206A1 (fr) Dérivé de cycle à six chaînons ayant une activité inhibitrice de trpv4
CA2784152A1 (fr) Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1-alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
WO2016098793A1 (fr) Dérivé thiazole ayant un groupe guanidyle cyclique
EP2632924A1 (fr) Diazaspiro[5.5]undécanes utiles comme antagonistes des récepteurs de l'orexine
JP4681526B2 (ja) 医薬組成物
KR102812440B1 (ko) 신규한 헤테로방향족 아미드 유도체 및 이를 함유하는 약제
WO2024180520A1 (fr) Nouveaux inhibiteurs d'atx
JP7611900B2 (ja) 縮合複素環化合物
DE60319254T2 (de) Pyrazolamide zur behandlung von hiv-infektionen
WO2019154329A1 (fr) Composé présentant une activité inhibitrice de bet, son procédé de préparation et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24763350

Country of ref document: EP

Kind code of ref document: A1